Microphysiological Systems in Drug Testing: Revolutionizing Preclinical Evaluation for Modern Medicine

Abstract

Microphysiological systems (MPS), also known as organ-on-a-chip technologies, represent a groundbreaking advancement in preclinical drug testing. By recapitulating key aspects of human physiology and organ function on microscale platforms, MPS bridge the translational gap between conventional in vitro assays and in vivo studies. This review examines the scientific basis, clinical relevance, and practical applications of MPS in drug development, with a focus on recent evidence, mechanistic insights, and guideline-based recommendations. We discuss epidemiological considerations, mechanistic underpinnings, critical risk factors, diagnostic approaches, management strategies, and emerging trends in the field. Ultimately, MPS hold the promise of enhancing drug safety and efficacy assessment, reducing reliance on animal models, and accelerating the translation of new therapeutics to clinical practice.

Introduction

The pharmaceutical industry faces significant challenges in translating preclinical findings into successful clinical outcomes. Traditional drug testing models, such as two-dimensional (2D) cell cultures and animal models, often fail to accurately predict human responses, leading to high attrition rates and substantial economic losses. Microphysiological systems (MPS) have emerged as transformative platforms that mimic the structural, functional, and microenvironmental features of human tissues and organs. By integrating living cells with microfluidic engineering, MPS enable the dynamic study of human pathophysiology, drug pharmacokinetics, and pharmacodynamics under controlled conditions. This review aims to provide clinicians and researchers with a comprehensive overview of MPS, emphasizing their scientific foundation, clinical relevance, and integration into drug development pipelines.

Epidemiology / Disease Burden

Drug development is notoriously resource-intensive, with estimates suggesting that over 90% of candidates fail to reach the market due to lack of efficacy or unforeseen toxicity in humans. The burden of adverse drug reactions (ADRs) remains a major public health concern, accounting for significant morbidity, mortality, and healthcare expenditures globally. The inability of conventional preclinical models to predict human-specific responses is a key driver of these challenges. MPS offer an opportunity to mitigate this burden by providing more physiologically relevant drug testing platforms, potentially reducing the incidence of ADRs and improving patient outcomes.

Pathophysiology

MPS are engineered to replicate the cellular architecture, microenvironment, and biomechanical cues present in human organs. These systems utilize microfluidic channels to deliver nutrients, remove waste, and apply shear stress, closely mimicking in vivo conditions. By incorporating multiple cell types and extracellular matrix components, MPS can model complex interactions such as inflammation, fibrosis, and tissue remodeling. For example, liver-on-a-chip devices mimic hepatic zonation and metabolic gradients, enabling detailed studies of drug metabolism and hepatotoxicity. Similarly, heart-on-a-chip and lung-on-a-chip platforms replicate electrophysiological and gas exchange functions, respectively. These mechanistic features underpin the superior predictive capacity of MPS compared to traditional models.

Risk Factors

While MPS offer significant advantages, several risk factors must be considered to ensure their effective application. Technical variability in device fabrication, cell sourcing, and culture conditions can impact reproducibility and data interpretation. The choice of cell type primary, immortalized, or induced pluripotent stem cell (iPSC)-derived cells affects physiological fidelity and scalability. Additionally, the complexity of multi-organ MPS platforms introduces challenges in inter-organ crosstalk and systemic pharmacokinetics modeling. Regulatory acceptance and standardization remain ongoing hurdles, necessitating rigorous validation and quality control protocols.

Clinical Features

The clinical utility of MPS lies in their ability to recapitulate patient-specific responses and disease phenotypes. Patient-derived cells integrated into MPS enable personalized drug screening, identification of idiosyncratic toxicities, and modeling of rare diseases. For instance, cardiac MPS have been used to predict drug-induced QT prolongation, a major cause of drug withdrawal. Liver MPS can detect cholestatic or steatotic drug effects, while kidney MPS facilitate nephrotoxicity assessment. Importantly, MPS allow longitudinal monitoring of tissue responses and biomarker release, providing clinically relevant endpoints for drug evaluation.

Diagnosis

In the context of drug testing, diagnosis refers to the detection and characterization of drug-induced effects on tissue function and viability. MPS facilitate real-time monitoring of physiological parameters such as contractility, barrier integrity, metabolic activity, and electrophysiological properties. Advanced imaging, biosensing, and omics technologies can be integrated with MPS for high-content analysis of cellular responses. These diagnostic capabilities enable early identification of off-target effects, elucidation of mechanisms of toxicity, and validation of pharmacodynamic biomarkers, supporting informed decision-making in drug development.

Treatment & Management

MPS are increasingly being adopted by pharmaceutical companies and academic laboratories for lead optimization, safety testing, and disease modeling. Their use can inform dose selection, identify therapeutic windows, and reduce the risk of late-stage clinical failures. In the management of drug development pipelines, MPS offer a cost-effective alternative to extensive animal studies and enable rapid screening of compound libraries. For clinicians, MPS data can support rational prescribing, guide drug repurposing efforts, and inform patient stratification strategies, ultimately enhancing therapeutic efficacy and safety.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable progress in the design and application of MPS. Multi-organ chips now enable the study of systemic pharmacokinetics and inter-organ interactions, closely reflecting human physiology. Advances in 3D bioprinting and tissue engineering have improved the structural complexity and scalability of MPS. Integration with artificial intelligence and machine learning is facilitating automated data analysis and predictive modeling. Notably, the COVID-19 pandemic accelerated the use of lung and vascular MPS for antiviral drug screening and pathophysiology research. Regulatory agencies, including the FDA, are increasingly recognizing MPS as qualified tools for preclinical safety testing, heralding a new era in drug development.

Guideline Recommendations

Current guidelines from regulatory authorities and professional societies emphasize the need for robust validation and standardization of MPS platforms. The FDA and European Medicines Agency (EMA) encourage the use of MPS data to supplement traditional preclinical studies, particularly for assessing human-specific toxicity. Best practices include the use of well-characterized cell sources, standardized protocols, and rigorous quality control measures. Collaborative efforts, such as the IQ Consortium and Tissue Chip Consortium, are working to establish consensus standards and facilitate regulatory acceptance. Clinicians and researchers are advised to interpret MPS data in the context of complementary in vitro, in vivo, and clinical findings.

Conclusion

Microphysiological systems are poised to revolutionize drug testing by providing physiologically relevant, mechanism-based insights into drug efficacy and safety. Their adoption promises to enhance the predictive power of preclinical studies, reduce reliance on animal models, and accelerate the development of safer, more effective therapeutics. Ongoing advances in MPS technology, standardization, and regulatory acceptance will further solidify their role in modern medicine. For healthcare professionals, understanding the capabilities and limitations of MPS is essential for integrating cutting-edge evidence into clinical practice and advancing patient care.